×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
Day 1 - Session 3: PIII Clinical Trial Waiver in India
Session Chair(s)
Nagaraj Bannur
Head-Regulatory Affairs and Patient Safety, India and Subcontinent
AstraZeneca Pharma India Limited, India
Speaker(s)
Session 3.2: Clinical Research in India - challenges and way forward
Suneela Milind Thatte
IQVIA, India
Vice President, Global Operations